These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 1981370)

  • 41. Once-a-day therapy of cefpodoxime proxetil for respiratory tract infections.
    Sawae Y; Ninomiya K; Sumida I; Inoue T; Takaki K; Okada K; Kumagai Y; Ishimaru T; Shimono N; Misumi H
    J Chemother; 1995 Nov; 7 Suppl 4():134-6. PubMed ID: 8904134
    [No Abstract]   [Full Text] [Related]  

  • 42. Cefpodoxime proxetil: a new, broad-spectrum, oral cephalosporin.
    Chocas EC; Paap CM; Godley PJ
    Ann Pharmacother; 1993 Nov; 27(11):1369-77. PubMed ID: 8286813
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cefpodoxime proxetil in the treatment of skin and soft tissue infections.
    Tack KJ; Wilks NE; Semerdjian G; Frazier CH; Shirin K; Puopolo A; Crossland SG; Goffe BS; Millikan L
    Drugs; 1991; 42 Suppl 3():51-6. PubMed ID: 1726208
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The comparative plasma pharmacokinetics of intravenous cefpodoxime sodium and oral cefpodoxime proxetil in beagle dogs.
    Brown SA; Boucher JF; Hubbard VL; Prough MJ; Flook TF
    J Vet Pharmacol Ther; 2007 Aug; 30(4):320-6. PubMed ID: 17610405
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An efficient one-pot reaction for selective fluorimetric determination of cefpodoxime and its prodrug.
    Mohamed NA; Abdel-Wadood HM; Ahmed S
    Talanta; 2011 Sep; 85(4):2121-7. PubMed ID: 21872067
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gastro-retentive dosage form for improving bioavailability of Cefpodoxime proxetil in rats.
    Kakumanu VK; Arora VK; Bansal AK
    Yakugaku Zasshi; 2008 Mar; 128(3):439-45. PubMed ID: 18311064
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of cefprozil, cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten.
    Schatz BS; Karavokiros KT; Taeubel MA; Itokazu GS
    Ann Pharmacother; 1996 Mar; 30(3):258-68. PubMed ID: 8833562
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Application of high-performance liquid chromatography hyphenated techniques for identification of degradation products of cefpodoxime proxetil.
    Fukutsu N; Kawasaki T; Saito K; Nakazawa H
    J Chromatogr A; 2006 Oct; 1129(2):153-9. PubMed ID: 16846608
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antibacterial activity of cefpodoxime in vitro.
    Liu YC; Huang WK; Cheng DL
    Chemotherapy; 1997; 43(1):21-6. PubMed ID: 8996737
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Clinical studies on cefpodoxime proxetil in the pediatric fields].
    Watanabe A; Koshinami M
    Jpn J Antibiot; 1989 Jul; 42(7):1471-6. PubMed ID: 2810723
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Determination of the third generation oral cephalosporin cefpodoxime in biological fluids by high-speed high-performance liquid chromatography.
    Molina F; Jehl F; Gallion C; Penner F; Monteil H
    J Chromatogr; 1991 Jan; 563(1):205-10. PubMed ID: 2061390
    [No Abstract]   [Full Text] [Related]  

  • 52. Comparison of oral cefpodoxime proxetil and penicillin V potassium in the treatment of group A streptococcal pharyngitis/tonsillitis. The Cefpodoxime Pharyngitis Study Group.
    Brown RJ; Batts DH; Hughes GS; Greenwald CA
    Clin Ther; 1991; 13(5):579-88. PubMed ID: 1799915
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Clinical evaluation of cefpodoxime proxetil in the treatment of skin and soft tissue infections. A double blind comparison of cefpodoxime proxetil and cefaclor].
    Yura J; Shinagawa N; Mizuno A; Watanabe S; Ando M; Sakai K; Ueda T; Morimoto K; Nakamura T; Hashimoto I
    Jpn J Antibiot; 1988 Oct; 41(10):1517-37. PubMed ID: 3060626
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [(New antimicrobial agent series XLIV): cefpodoxime proxetil].
    Kumazawa J
    Jpn J Antibiot; 1993 Sep; 46(9):749-72. PubMed ID: 8254896
    [No Abstract]   [Full Text] [Related]  

  • 55. XXIV International Congress of the World Federation of Hemophilia. Montreal, Canada, 16-21 July 2000. Abstracts.
    Haemophilia; 2000 Jun; 6(4):199-470. PubMed ID: 10985166
    [No Abstract]   [Full Text] [Related]  

  • 56. XIIth International Congress of Pharmacology. Molecular mechanisms to modern medicine. Montreal, Canada, 24-29 July 1994. Abstracts.
    Can J Physiol Pharmacol; 1994; 72 Suppl 1():1-614. PubMed ID: 7954104
    [No Abstract]   [Full Text] [Related]  

  • 57. A guide to the treatment of lower respiratory tract infections.
    Vogel F
    Drugs; 1995 Jul; 50(1):62-72. PubMed ID: 7588090
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cefpodoxime proxetil: a third-generation oral cephalosporin. International Congress for Infectious Diseases, Montreal, Canada, 15-19 July 1990.
    J Antimicrob Chemother; 1990 Dec; 26 Suppl E():1-101. PubMed ID: 1981370
    [No Abstract]   [Full Text] [Related]  

  • 59. Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients.
    Fulton B; Perry CM
    Paediatr Drugs; 2001; 3(2):137-58. PubMed ID: 11269640
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cefpodoxime proxetil. An appraisal of its use in antibacterial cost-containment programmes, as stepdown and abbreviated therapy in respiratory tract infections.
    Balfour JA; Benfield P
    Pharmacoeconomics; 1996 Aug; 10(2):164-78. PubMed ID: 10163419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.